TC BioPharm shares are trading higher after the company received a European patent grant for the use of modified gamma delta cells in treating cancer and viral indications.
Portfolio Pulse from Benzinga Newsdesk
TC BioPharm's shares rose following the grant of a European patent for using modified gamma delta cells in cancer and viral treatments.
August 28, 2024 | 6:38 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
TC BioPharm's stock is trading higher due to the grant of a European patent for their innovative use of modified gamma delta cells in treating cancer and viral diseases.
The European patent grant is a significant milestone for TC BioPharm, potentially enhancing its market position and investor confidence. This development is likely to positively impact the stock price in the short term as it opens new opportunities for the company's cancer and viral treatment solutions.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100